Neurocrine reports Q4 2025 revenue $805.5M, EPS $1.48 GAAP; guides INGREZZA 2026 sales $2.7-2.8B

NEUROCRINE BIOSCIENCES INC

2025-FY EPS reported $4.67 revenue$2,860,500,000

Q4 total net product sales $798.3M (+29% YoY); full year $2.83B (+22% YoY).
INGREZZA Q4 sales $657.5M (+7% YoY); full year $2.51B (+9% YoY); 2026 guidance $2.7-2.8B.
CRENESSITY Q4 sales $135.3M (vs $1.7M YoY); full year $301.2M; 2,048 new patient start forms in FY.
GAAP diluted EPS Q4 $1.48 (vs $1.00); full year $4.67 (vs $3.29). Non-GAAP EPS Q4 $1.88 (vs $1.69).
Cash & marketable securities $2.54B at Dec 31, 2025; R&D and SG&A guidance provided for 2026.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.